Why Did STAAR Surgical Soar 46.02%? Alcon Acquisition

On August 5, 2025, Staar Surgical's stock surged by 46.02% in pre-market trading, driven by a significant acquisition announcement.

Alcon, a leading eye care company, has agreed to acquire all outstanding shares of STAAR Surgical for $28 per share in cash. This acquisition values STAAR Surgical at approximately $1.5 billion in equity value, representing a 59% premium to STAAR's 90-day Volume Weighted Average Price and a 51% premium to the closing price of STAAR common stock on August 4.

The acquisition includes the EVO family of lenses for vision correction, which are used for patients with moderate to high myopia, with or without astigmatism. This strategic move is expected to complement Alcon's laser vision correction business and be accretive to earnings in the second year post-acquisition.

The transaction is anticipated to close within six to twelve months and is not subject to a financing condition. Alcon intends to finance the acquisition through the issuance of short- and long-term credit facilities. The Boards of Directors of both Alcon and STAAR have unanimously approved the transaction.